AMIX
Autonomix Medical·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 3
MACD Death Cross
Ample Liquidity
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AMIX
Autonomix Medical, Inc.
A company that manufactures medical devices that identify and diagnose neurological diseases.
Healthcare Equipment and Supplies
06/10/2014
01/29/2024
NASDAQ Stock Exchange
8
03-31
Common stock
21 Waterway Avenue, Suite 300, The Woodlands, Texas 77380
--
Autonomix Medical, Inc., a Delaware corporation, was incorporated on June 10, 2014. The company is a development-stage medical device development company focused on advancing innovative technologies for the perception and treatment of diseases related to the nervous system. The company's first-in-class technology platform includes a catheter-based microchip sensing array capable of detecting and distinguishing neural signals with 1,000 times greater sensitivity than currently available transvascular technologies. The company is initially developing technology for patients with pancreatic cancer and pancreatitis, which can cause debilitating pain and require a more effective solution. The company's development work can be divided into two sub-parts: sensing and therapy, where sensing focuses on identifying neuronal activity that may be associated with disease with sufficient precision to make targeted therapy possible. The company's sensing catheters have been developed enough to demonstrate efficacy in animal models, and the company is currently improving the assembly of such catheters to meet the standards required for human use. At the same time, the company is preparing to conduct the first human trial to prove that transvascular ablation can relieve pancreatic cancer-related pain, with the goal of combining sensing and treatment in future pivotal clinical trials to enable commercial application of its technology.
Company Financials
EPS
AMIX has released its 2026 Q2 earnings. EPS was reported at -1.38, versus the expected -1.5, beating expectations. The chart below visualizes how AMIX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
